Masimo Corporation $MASI Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its position in Masimo Corporation (NASDAQ:MASI) by 45.4% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 20,897 shares of the medical equipment provider’s stock after selling 17,405 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Masimo were worth $3,532,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in Masimo by 58.4% in the 1st quarter. GAMMA Investing LLC now owns 738 shares of the medical equipment provider’s stock valued at $123,000 after buying an additional 272 shares during the period. Strs Ohio acquired a new position in Masimo in the 1st quarter valued at $6,686,000. Swedbank AB acquired a new position in shares of Masimo during the 1st quarter worth $12,645,000. Harbor Capital Advisors Inc. acquired a new position in shares of Masimo during the 2nd quarter worth $4,443,000. Finally, Intech Investment Management LLC grew its stake in shares of Masimo by 26.8% during the 1st quarter. Intech Investment Management LLC now owns 32,494 shares of the medical equipment provider’s stock worth $5,414,000 after purchasing an additional 6,872 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MASI. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Masimo in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Piper Sandler upped their price target on shares of Masimo from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 6th. BTIG Research reaffirmed a “buy” rating and set a $198.00 price target on shares of Masimo in a research note on Thursday, September 11th. Finally, Zacks Research raised shares of Masimo from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $194.60.

Masimo Price Performance

Shares of NASDAQ MASI opened at $147.01 on Tuesday. The stock has a market cap of $7.99 billion, a price-to-earnings ratio of -17.25 and a beta of 1.28. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57. The company’s 50-day moving average price is $145.59 and its 200 day moving average price is $154.59. Masimo Corporation has a 52 week low of $133.70 and a 52 week high of $194.88.

Masimo (NASDAQ:MASI) last released its earnings results on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share (EPS) for the quarter. The company had revenue of $617.00 million for the quarter. Masimo had a negative net margin of 24.85% and a positive return on equity of 26.54%. As a group, research analysts forecast that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insider Transactions at Masimo

In other news, Director William R. Jellison bought 3,000 shares of Masimo stock in a transaction on Monday, August 11th. The shares were bought at an average cost of $145.98 per share, for a total transaction of $437,940.00. Following the acquisition, the director owned 4,790 shares in the company, valued at approximately $699,244.20. This trade represents a 167.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 16.90% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.